- Alirocumab, Praluent: Clinical studies: An overwiev2016 | First Faculty of Medicine
- Inhibitor of PCSK9 protein - alirocumab in clinical trials, ODYSSEY program2018 | First Faculty of Medicine
- Alirocumab2016 | Third Faculty of Medicine
- Alirocumab in patients with familial hypercholesterolemia2016 | Faculty of Medicine in Hradec Králové
- Alirocumab, human monoclonal antibody in biological dyslipidemia treatment2016 | Faculty of Medicine in Pilsen
- Influence of alicumab therapy on development of cardiovascular mortality/morbidity after acute coronary syndrome2018 | Faculty of Medicine in Hradec Králové
- The commentary on the study: The efficacy of alicumab in patients with hypercholesterolaemia, depending on the type and dose of co-administered statin - a combined analysis of 8 clinical trials2017 | Faculty of Medicine in Hradec Králové
- Inhibitor proteinu PCSK9 - alirocumab v klinických studiích, program ODYSSEY2018 | First Faculty of Medicine
- Alirocumab in treatment of combined dyslipidemia2020 | Third Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. EFC11570Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: EFC11570Publication without faculty affiliation
- Research Report University Hospital for clinical assessment EFC11570Publication without faculty affiliation
- Contemporary and modern treatment of hyperlipoproteinemia2016 | First Faculty of Medicine
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Vliv snížení hladiny lipoproteinu (a) alirocumabem u pacientů s akutním koronárním syndromem na incidenci diabetu 2.typu2021 | First Faculty of Medicine
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome2018 | Publication without faculty affiliation
- The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition2017 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery2019 | Publication without faculty affiliation
- Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial2019 | Publication without faculty affiliation
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial2019 | Publication without faculty affiliation
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publication without faculty affiliation
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia2015 | First Faculty of Medicine
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent(R)2015 | First Faculty of Medicine
- Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial2019 | Publication without faculty affiliation
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publication without faculty affiliation
- Familial hypercholesterolemia2014 | First Faculty of Medicine